NeuroThera Secures U.S. Patent for Cannabinoid-Antibiotic Combo to Combat MRSA
Event summary
- NeuroThera Labs, a subsidiary of SciSparc, received a U.S. patent for its cannabinoid-enhanced antimicrobial technology on February 2, 2026.
- The patent covers compositions combining antibiotics with cannabinoids like THC and CBD to enhance efficacy against resistant bacterial strains, including MRSA.
- Preclinical studies showed the combination could restore antibiotic effectiveness while leveraging the safety profiles of existing drugs.
- The global antibiotics market is projected to reach $58 billion in 2026, driven by rising antimicrobial resistance.
The big picture
The patent strengthens NeuroThera's intellectual property in a market where antimicrobial resistance is a growing crisis, with MRSA alone causing 130,000 deaths globally in 2021. The technology addresses a critical gap as major pharmaceutical firms exit antibiotic development due to high costs and rapid resistance emergence. The global antibiotics market's projected growth to $58 billion by 2026 underscores the urgency for innovative solutions.
What we're watching
- Regulatory Pathway
- How NeuroThera will navigate clinical trials and regulatory approvals for its cannabinoid-antibiotic combination.
- Market Adoption
- Whether the technology can gain traction amid pharmaceutical industry reluctance to invest in new antibiotics.
- Competitive Positioning
- The pace at which NeuroThera can differentiate itself in the antimicrobial resistance space.
Related topics